Voluntis, AstraZeneca to Test Mobile App Supporting Patients with Platinum-Resistant Ovarian Cancer

Voluntis, AstraZeneca to Test Mobile App Supporting Patients with Platinum-Resistant Ovarian Cancer
Voluntis and AstraZeneca have extended their partnership to evaluate a mobile app, called eCO (eCediranib/Olaparib), to help women with platinum-resistant ovarian cancer report and manage their side effects. The approach is being developed for women receiving a combination of cediranib plus Lynparza (olaparib), and will be tested in the GY005 Phase 2/3 clinical trial (NCT02502266), which started in 2015 and is sponsored by the National Cancer Institute (NCI). The study aims to evaluate the efficacy of cediranib and Lynparza, given alone or in combination, in fighting cancers in the ovaries, fallopian tube, or peritoneum, a membrane lining the abdominal cavity and covering the abdominal organs. Lynparza, by AstraZeneca, works by preventing cancer cells from repairing damaged DNA, which causes them to die. The medicine is approved for ovarian cancer patients who responded to prior platinum-based chemotherapy, or for those with BRCA mutations who received three or more prior chemotherapies. Cediranib, also by AstraZeneca, is being developed to block the formation of new blood vessels required for a tumor to grow. Only patients whose disease did not respond to platinum-based chemotherapy or stopped responding to such medications will be admitted in the study. The results will be compared to patients treated with standard chemotherapy. Primary endpoints of the study include the time a patient lives without disease progression and overall survival. Secondary endpoints include objective response rate and incidence of adverse events, among others, all to be assessed up to five years post-treatment. Women enrolled in the study will be given eCO along with their treatment to help them manage their symptoms of high blood pressure and diarrhea, sometimes a
Subscribe or to access all post and page content.